Apotex Pharmachem Inc.

Brantford Chemicals Inc.

Apotex Inc.

Acic (canada) Inc.

Other

Gamini Weeratunga

Prabhudas Bodhuri

Stephen E Horne

Keshava Ks Murthy

Derek John Norris

Boris Gorin

Yajun Zhao

Carlos Zetina-Rocha

K S Murthy

Allan W Rey

Bhaskar Reddy Guntoori

Derrick L Clive

Melanie R A Green

K S Keshava Murthy

Bruno K Radatus

Avedis Karadeolian

Cameron L McPhail

Mohammed Abdul Raheem

Uma Kotipalli

Murali Kondamreddy

Peter Garth Blazecka

Craig Stewart

Andrew Burchat

Eduardo Gustavo Cammisa

Fabio E S Souza

Zhi-Xian Wang

Elena Bejan

Probal Kanti Datta

Sammy Chris Duncan

Alfredo Paul Ceccarelli

Jaipal Reddy Nagireddy

Nageib Mohamed

Michael R Emmett

Eckardt C G Wolf

Michael B Johansen

Keshava K S Murthy

Robert P Smyj

Bogdan M Comanita

Nalini Nagireddy

Laura Kaye McConachie

Shawn Young

Kaarina K Milnes

Burchat Andrew

Kanwar Pal Sidhu

Ks Keshava Murthy

Tianhao Zhou

The present invention provides processes for the preparation of Acalabrutinib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for coupling of a compound of Formula (5) and 2-butynoic acid in the presence of Carbodiimide (8) to afford Acalabrutinib (1). 

Process for the preparation of acalabrutinib

The present invention provides processes for the preparation of Veliparib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for the production of the compound of Formula (3), or a salt thereof, and cyclization to afford Veliparib (1). 

Processes for the preparation of Veliparib and intermediates thereof

The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1). 

Processes for the preparation of apalutamide and intermediates thereof

The present invention provides processes for the preparation of Lesinurad (1), as well as intermediates useful in the preparation thereof. In particular, the processes of the invention utilize novel intermediate compounds of Formulas (3) and (11), which provide improvements over the known processes for the preparation of Lesinurad (1). 

Processes for the preparation of lesinurad and intermediates thereof

The present invention provides processes for the preparation of Tasimelteon (1), as well as processes for the preparation of intermediates of Formulas (2), (3) and (4) useful in the preparation of Tasimelteon (1). 

Processes for the preparation of Tasimelteon and intermediates thereof

This invention provides processes for preparation of 3-alkyl indoles of Formula 1: wherein A, Aand Aare independently selected from the group consisting of: H, X, OR, CN, CONRand C0R; Ris C-Calkyl; Ris H or C-Calkyl; Ris C-Calkyl; LG is a leaving group; X is a halogen; and n is 1, 2 or 3.

Processes for the preparation of 3-alkyl indoles

Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.

Forms of vilazodone and processes for the preparation thereof

Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).

Solid forms of nilotinib hydrochloride

There is provided a crystalline form of Lapatinib, termed APO-I, and methods for making APO-I. There is also provided a crystalline solvate form of Lapatinib, termed APO-II, and methods for making APO-II.

Polymorphic forms of Lapatinib ditosylate and processes for their preparation

There is provided processes for preparing Lapatinib and pharmaceutically acceptable salts thereof by the reductive amination of the aldehyde of Formula II by treatment with 2-methanesulphonylethylamine followed by catalytic hydrogenation in the presence of a suitable hydrogenation catalyst.

Process for the preparation of lapatinib and its ditosylate salt

There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

Polymorphic forms of Warfarin potassium and preparations thereof

Provided are process for the preparation of (R)- and/or (S)-Rivaroxaban, and compounds which are intermediate compounds used in the processes for the preparation of (R)- and/or (S)-Rivaroxaban.

Processes for the preparation of rivaroxaban and intermediates thereof

In illustrative embodiments, there is provided an amorphous form of L-arginine salt of perindopril which may be particularly suitable for pharmaceutical applications, and processes for preparing said form.

Amorphous form of an L-arginine salt of perindopril and processes for preparation thereof

This invention provides a process for the preparation of S-Rivaroxaban and/or R-Rivaroxaban comprising reacting, in the presence of a first base, a compound of Formula 9: with a compound of Formula 8: 

Growing community of inventors

Ancaster, Canada

Gamini Weeratunga